176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Authors :: S. Nagao
P. Harter
A. Leary
C. Cropet
S. Pignata
K. Fujiwara
A.J. Gonzalez Martin
G. Bogner
I. Vergote
N. Colombo
J. Maenpaa
F. Selle
B. Schmalfeldt
G. Scambia
E.M. Guerra Alia
C. Lefeuvre-Plesse
A. Belau
A. Lortholary
M. Gropp-Meier
E. Pujade-Lauraine
I. Ray-Coquard
Source :: Annals of Oncology. 33:S1503-S1504
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Full Text Access

Tools